Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Ludlam

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Thrombosis Research|December 31, 2003
Preserved endothelial vasomotion and fibrinolytic function in patients with acute stent thrombosis or in-stent restenosisStanley Chia, Ian L Megson, Christopher A Ludlam, et al.
Clinical Science (London, England : 1979)|November 29, 2005
Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart diseaseSimon D Robinson, Pamela Dawson, Christopher A Ludlam, et al.
British Journal of Haematology|March 5, 2003
A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluationChristopher A Ludlam, Mark P Smith, Massimo Morfini, et al.
Journal of the American College of Cardiology|September 13, 2002
Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapyFraser N Witherow, Pamela Dawson, Christopher A Ludlam, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 15, 2003
Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humansStanley Chia, Motaz Qadan, Richard Newton, et al.
Clinical Science (London, England : 1979)|September 16, 2004
Endothelial dysfunction in patients with recent myocardial infarction and hyperhomocysteinaemia: effects of vitamin supplementationStanley Chia, Robert Wilson, Christopher A Ludlam, et al.
Hypertension (Dallas, Tex. : 1979)|October 20, 2004
Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibitionNicholas L M Cruden, Keith A A Fox, Christopher A Ludlam, et al.
Diabetes Care|July 1, 2010
Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetesRohana J Wright, David E Newby, David Stirling, et al.
Journal of Vascular Surgery|April 5, 2002
The prevalence of thrombophilia in patients with chronic venous leg ulcerationRhoda K Mackenzie, Christopher A Ludlam, C Vaughan Ruckley, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 19, 2003
Bradykinin receptor antagonism and endothelial tissue plasminogen activator release in humansFraser N Witherow, Pamela Dawson, Christopher A Ludlam, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Thrombosis Research|December 31, 2003
Preserved endothelial vasomotion and fibrinolytic function in patients with acute stent thrombosis or in-stent restenosisStanley Chia, Ian L Megson, Christopher A Ludlam, et al.
Clinical Science (London, England : 1979)|November 29, 2005
Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart diseaseSimon D Robinson, Pamela Dawson, Christopher A Ludlam, et al.
British Journal of Haematology|March 5, 2003
A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluationChristopher A Ludlam, Mark P Smith, Massimo Morfini, et al.
Journal of the American College of Cardiology|September 13, 2002
Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapyFraser N Witherow, Pamela Dawson, Christopher A Ludlam, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 15, 2003
Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humansStanley Chia, Motaz Qadan, Richard Newton, et al.
Clinical Science (London, England : 1979)|September 16, 2004
Endothelial dysfunction in patients with recent myocardial infarction and hyperhomocysteinaemia: effects of vitamin supplementationStanley Chia, Robert Wilson, Christopher A Ludlam, et al.
Hypertension (Dallas, Tex. : 1979)|October 20, 2004
Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibitionNicholas L M Cruden, Keith A A Fox, Christopher A Ludlam, et al.
Diabetes Care|July 1, 2010
Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetesRohana J Wright, David E Newby, David Stirling, et al.
Journal of Vascular Surgery|April 5, 2002
The prevalence of thrombophilia in patients with chronic venous leg ulcerationRhoda K Mackenzie, Christopher A Ludlam, C Vaughan Ruckley, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 19, 2003
Bradykinin receptor antagonism and endothelial tissue plasminogen activator release in humansFraser N Witherow, Pamela Dawson, Christopher A Ludlam, et al.
Pageof 4